



SEBI REGISTRATION NUMBER: INH100006427
BSE ENLISTMENT NUMBER: 5308

XX XX XXXX

VIJAYA DIAGNOSTIC CENTRE LIMITED



RECOMMENDATION

BUY

FACE VALUE

₹1

MARKET PRICE

XXX

BSE CODE

543350


AS OF XX XX XXXX

TARGET PRICE

XXX

NSE CODE

VIJAYA



ABOUT THE COMPANY

Vijaya Diagnostic Centre Limited was incorporated in 1981 and is one of South India's largest diagnostic chains, headquartered in Hyderabad. The Company operates a hub-and-spoke network of diagnostic centres offering pathology and radiology services, delivering accurate and affordable healthcare diagnostics to patients across its service regions.

The Company provides a comprehensive range of services including routine pathology tests, advanced molecular diagnostics, MRI, CT, X-ray, and other imaging modalities. Vijaya Diagnostic's integrated model combines collection centres, processing hubs, and full-service centres, enabling efficient sample logistics and rapid turnaround of test results across Telangana, Andhra Pradesh, and select other states.

Vijaya Diagnostic Centre continues to expand its geographic presence through organic centre additions and strategic acquisitions, strengthening its brand in underpenetrated markets. The Company is investing in technology platforms, home collection services, and digital health initiatives to enhance customer experience and operational efficiency.







Q3 FY26 Performance Snapshot



Financial Performance




Key Metrics




YOY Growth %



Geographical Contribution



Wellness Share%




1. Total number of centres as at 31-Dec-25




9M FY26 Performance Snapshot



Financial Performance




Key Metrics




YOY Growth %



Geographical Contribution



Wellness Share%






1. Total number of centres as at 31-Dec-25






Key Financial Highlights – Q3 FY26 & 9M FY26



Key Financials




Revenue Mix





Key Operational Highlights





Consolidated Profit & Loss Statement



(INR Mn)

Particulars	Q3 FY26	Q3 FY25	Y-o-Y	Q2 FY26	Q-o-Q	9MFY26	9MFY25	Y-o-Y	FY25	FY24	Y-o-Y
Revenue from operations	2,052.1	1,689.8	21.4%	2,015.6	1.8%	5,948.3	5,081.5	17.1%	6,813.9	5,478.1	24.4%
Cost of materials consumed	240.3	208.5	15.2%	243.2	-1.2%	697.6	626.0	11.4%	847.6	654.4	29.5%
Gross Profit	1,811.9	1,481.3	22.3%	1,772.4	2.2%	5,250.7	4,455.5	17.8%	5,966.3	4,823.7	23.7%
Gross Profit (%)	88.3%	87.7%	63 bps	87.9%	36 bps	88.3%	87.7%	59 bps	87.6%	88.1%	-49 bps
Employee benefits expense	330.4	285.5	15.7%	322.6	2.4%	969.0	837.5	15.7%	1,121.5	902.2	24.3%
Other expenses	620.9	524.4	18.4%	631.6	-1.7%	1,867.5	1,574.5	18.6%	2,112.6	1,712.5	23.4%
EBITDA	860.5	671.3	28.2%	818.3	5.2%	2,414.1	2,043.5	18.1%	2,732.2	2,209.0	23.7%
EBITDA Margin (%)	41.9%	39.7%	221 bps	40.6%	134 bps	40.6%	40.2%	37 bps	40.1%	40.3%	-23 bps
Other income	51.0	47.0	8.6%	62.5	-18.4%	184.0	127.7	44.1%	183.2	208.2	-12.0%
Depreciation and amortization expense	243.4	183.0	33.0%	222.7	9.3%	675.0	517.8	30.4%	706.0	570.0	23.9%
EBIT	668.2	535.2	24.8%	658.1	1.5%	1,923.2	1,653.5	16.3%	2,209.4	1,847.2	19.6%
Finance costs	85.9	68.2	26.0%	78.3	9.8%	239.1	195.5	22.3%	267.4	239.9	11.5%
Profit before Exceptional Items & Tax	582.2	467.0	24.7%	579.8	0.4%	1,684.1	1,457.9	15.5%	1,941.9	1,607.3	20.8%
Exceptional Items	0.0	0.0	-	0.0	-	0.0	0.0	-	10.3	20.5	-49.8%
Profit before Tax	582.2	467.0	24.7%	579.8	0.4%	1,684.1	1,457.9	15.5%	1,931.6	1,586.8	21.7%
Tax expenses	150.5	114.1	31.9%	147.0	2.4%	433.6	368.6	17.6%	493.7	390.4	26.4%
Profit before Minority Interest	431.8	353.0	22.3%	432.8	-0.2%	1,250.5	1,089.3	14.8%	1,437.9	1,196.4	20.2%
Minority Interest	0.0	0.0	-	0.0	-	0.0	0.0	-	0.0	8.1	-100.0%
Profit after Tax (PAT)	431.8	353.0	22.3%	432.8	-0.2%	1,250.5	1,089.3	14.8%	1,437.9	1,188.3	21.0%
PAT Margin (%)	21.0%	20.9%	15 bps	21.5%	-43 bps	21.0%	21.4%	-41 bps	21.1%	21.7%	-59 bps
EPS – Basic (INR)*	4.2	3.4	22.2%	4.2	-0.3%	12.2	10.6	14.7%	14.0	11.6	20.4%

*Not annualized



1 Strengthening Senior Leadership Team for the Next Leg of Growth



 **Chief Financial Officer (CFO)**
Ankit Shah

Total Experience: 20+ years
Last Experience: Chief Financial Officer - INCOR Group (Omni Hospitals)

Chartered Accountant 

Broad areas of management includes Finance Budgeting Compliance


 **Chief Technology Officer (CTO)**
Sai Prasad


Total Experience: 20+ years
Last Experience: Director Software Engineering - UnitedHealth Group

NIT, Mysore 

Broad areas of management includes IT - Operations Data Security Strategic IT Initiatives

 **Sivaramaraju Vegesna, CFA** → Rejoined the company as → **Chief Operating Officer (COO)**

7 years Spent at 

Broad areas of management includes Operations Sales HR Strategic Initiatives



2 Inaugurated a state-of-the-art Hub in Phoolbagan, West Bengal




Inaugurated State-of-the-Art Hub in Phoolbagan in the 2nd week of Dec-25 in line with our strategy of creating dense network in WB



Phoolbagan

Facility houses advanced equipment including region's 1st 3T MRI

Serves as major transit hub with densely population featuring several established private and government hospitals






3 Inaugurated a state-of-the-art Hub in Diamond Harbour, West Bengal



Inaugurated State-of-the-Art Hub in Diamond Harbour in the 2nd week of Dec-25 in line with our strategy of creating dense network in WB



5,250+ sq. ft. facility houses advanced equipment including region's 1st 3T MRI

The urban area is densely populated, featuring several prominent hospitals and excellent connectivity






4 Inaugurated a state-of-the-art Hub in Nandyal, AP




Inaugurated State-of-the-Art Hub in Nandyal in the 1st week of Oct-25 in line with our strategy of broadening presence in tier 2 / 3 geographies of our core markets



8,000 sq.f.t facility houses an automated lab & advanced equipment including region's 1st 3T MRI

Vijaya already has established footprint in Nandyal through a spoke





5 Inaugurated a state-of-the-art Hub in Khammam, Telangana



Inaugurated State-of-the-Art Hub in Khammam in the 4th week of Oct-25 in line with our strategy of broadening presence in tier 2 / 3 geographies of our core markets



10,000+ sq.f.t facility houses an automated lab and advanced equipment including a 3T MRI and 160 slice cardiac CT

Marks our entry into the promising region of Khammam






Expanding Strategically in Alignment with our Vision



Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
- Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition
- Aspire to consolidate our presence gradually by building a denser network



East India Strategy

- Inaugurated 5 hubs in 9M FY26 under the Vijaya brand in West Bengal
- Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network

Expansion into Neighbouring State

- Inaugurated 2 hubs in HSR Layout and Yelahanka, Bengaluru in Q1 FY26
- Planning to add few more hubs in FY27





Core Market Strategy


- Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
- Operationalized 2 hubs in Nandyal and Khammam (AP & Telangana) in October 2025



Expansion Plans - Upcoming Hubs and Spokes Centres



Geography	Count & Type	Tentative Timelines for Commencement
 Hyderabad	1 Spoke 5 Spokes	H2 FY26 H1 FY27
 RoAPT	3 Spokes	H1 FY27
 Bengaluru	1 Hub 1 Spoke	H1 FY27
 West Bengal	1 Spoke	H1 FY27






Vijaya at a Glance



Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 162 state-of-the-art centres spread across 27 cities & towns

Evolved from a regional player to a player with presence in multiple geographies ...



... While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices

40+ Years of Vintage

17 labs with NABL Accreditation

Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy

27 Cities and towns across India

Largest B2C integrated Player in India

300+ Doctors

Radiologist & Pathologist network

~4.51 Mn Footfalls ⁽¹⁾

Trusted by every Age group

~16.22 Mn Tests ⁽¹⁾

Most preferred Diagnostic Centre

1. Footfall and Tests for the 12 months ended 31-Dec-25




Integrated Diagnostics Player Offering One-Stop Solution



Complete Range of Diagnostic Services under One Roof

Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience



1. Revenue mix for Q3 FY26




Dominant Position in Telangana & AP Markets with a Strong Brand Recall ...



Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets

Present in Key Geographies of AP & Telangana



69⁽¹⁾ %

Hyderabad Revenue Contribution



20⁽¹⁾ %

RoAPT Revenue Contribution

A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests





1. For Q3 FY26



... and Driving Geographical Diversification through Strategic Expansion



Geographical Revenue Mix




Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience

RoAPT - Rest of AP and Telangana




Boosting Accessibility with Best-in-class Online Services & Home Collections



1. Patient can track his / her health trends over time 2. Post Collection



Robust Technical Capabilities with State-of-the-art IT Infrastructure



Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling...

Standardization across our operations

Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**

Reduce incidence of errors due to **Low Human Intervention**

Monitor Technical Operations

Provide **Uniform Experience** to customers from booking appointments to accessing reports online

Key Suppliers



- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services

Note: Data above is as at 31-Dec-25



State-of-the-art Infrastructure (1/3)





State-of-the-art Infrastructure (2/3)





State-of-the-art Infrastructure (3/3)







Advanced Equipment in Place to Deliver High Quality Services (1/2)





Advanced Equipment in Place to Deliver High Quality Services (2/2)







Robust Operational Metrics




Diagnostic Centre (Nos)



Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)


Impact of COVID-19



Revenue per Test (INR)



Revenue per Footfall (INR)









Consistent Financial Performance




(INR Mn)



EBIDTA Margin (%)



PAT Margin (%)



Integrated business model with high B2C concentration (~93%) and a strong brand recall has resulted in Industry leading margins


Note: With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value ("WDV") method to Straight Line Method ("SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Due to the aforesaid change, the PAT for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively




Sustainable Cash Generation & Increasing Return Ratios




Surplus Cash




CFO ⁽¹⁾ / EBIDTA (%)



RoCE Pre-Tax ⁽²⁾ (%)



RoE (%)



1. CFO = Cash flow from Operations 2. ROCE (Pre-tax): PBIT ex Other income / (Networth + Long Term Debt)



QUARTERLY RESULTS

AS OF DEC '25

Consolidated Quarterly Results	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24
Net Sales/Income from operations	205.21	201.56	188.05	173.24	168.98
Other Operating Income	--	--	--	--	--
Total Income From Operations	205.21	201.56	188.05	173.24	168.98
Expenditure	--	--	--	--	--
Consumption of Raw Materials	24.03	24.32	21.41	22.17	20.85
Purchase of Traded Goods	--	--	--	--	--
Increase/Decrease in Stocks	--	--	--	--	--
Power & Fuel	--	--	--	--	--
Employees Cost	33.04	32.26	31.61	28.40	28.55
Depreciation	24.34	22.27	20.89	18.82	18.30
Excise Duty	--	--	--	--	--
Admin. And Selling Expenses	--	--	--	--	--
R & D Expenses	--	--	--	--	--
Provisions And Contingencies	--	--	--	--	--
Exp. Capitalised	--	--	--	--	--
Other Expenses	62.09	63.16	61.50	53.81	52.44
P/L Before Other Inc., Int., Excpt. Items & Tax	61.72	59.56	52.64	50.04	48.83
Other Income	5.10	6.25	7.05	5.55	4.70
P/L Before Int., Excpt. Items & Tax	66.82	65.81	59.69	55.59	53.52
Interest	8.59	7.83	7.49	7.19	6.82
P/L Before Exceptional Items & Tax	58.22	57.98	52.21	48.40	46.70
Exceptional Items	--	--	--	-1.03	--
P/L Before Tax	58.22	57.98	52.21	47.37	46.70
Tax	15.05	14.70	13.62	12.51	11.41
P/L After Tax from Ordinary Activities	43.18	43.28	38.59	34.86	35.30
Prior Year Adjustments	--	--	--	--	--
Extra Ordinary Items	--	--	--	--	--
Net Profit/(Loss) For the Period	43.18	43.28	38.59	34.86	35.30
Minority Interest	--	--	-0.25	-0.23	-0.14
Share Of P/L Of Associates	--	--	--	--	--
Net P/L After M.I & Associates	43.18	43.28	38.34	34.64	35.16
Equity Share Capital	10.27	10.27	10.27	10.26	10.26
Reserves Excluding Revaluation Reserves	--	--	--	--	--
Equity Dividend Rate (%)	--	--	--	--	--
EPS Before Extra Ordinary	--	--	--	--	--
Basic EPS	4.20	4.21	3.76	3.38	3.42
Diluted EPS	4.19	4.20	3.75	3.37	3.42
EPS After Extra Ordinary	--	--	--	--	--
Basic EPS	4.20	4.21	3.76	3.38	3.42
Diluted EPS	4.19	4.20	3.75	3.37	3.42



ANNUAL RESULTS

AS OF MAR '25

Consolidated Annual Results	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
Net Sales/Income from operations	681.39	547.81	459.22	462.37	376.75
Other Operating Income	--	--	--	--	--
Total Income From Operations	681.39	547.81	459.22	462.37	376.75
Expenditure	--	--	--	--	--
Consumption of Raw Materials	84.76	65.44	58.88	71.50	57.09
Purchase of Traded Goods	--	--	--	--	--
Increase/Decrease in Stocks	--	--	--	--	--
Power & Fuel	--	--	--	--	--
Employees Cost	112.15	90.22	78.48	70.66	57.43
Depreciation	70.60	57.00	61.72	52.69	50.45
Excise Duty	--	--	--	--	--
Admin. And Selling Expenses	--	--	--	--	--
R & D Expenses	--	--	--	--	--
Provisions And Contingencies	--	--	--	--	--
Exp. Capitalised	--	--	--	--	--
Other Expenses	211.26	171.25	139.84	116.52	96.24
P/L Before Other Inc., Int., Excpt. Items & Tax	202.62	163.90	120.31	151.00	115.52
Other Income	18.32	20.82	14.15	12.83	11.85
P/L Before Int., Excpt. Items & Tax	220.94	184.72	134.46	163.83	127.37
Interest	26.74	23.99	20.95	16.45	15.25
P/L Before Exceptional Items & Tax	194.19	160.73	113.51	147.38	112.12
Exceptional Items	-1.03	-2.05	--	--	--
P/L Before Tax	193.16	158.68	113.51	147.38	112.12
Tax	49.37	39.04	28.30	36.72	27.00
P/L After Tax from Ordinary Activities	143.79	119.64	85.21	110.67	85.13
Prior Year Adjustments	--	--	--	--	--
Extra Ordinary Items	--	--	--	--	--
Net Profit/(Loss) For the Period	143.79	119.64	85.21	110.67	85.13
Minority Interest	-0.72	-0.81	-0.58	-0.99	-0.65
Share Of P/L Of Associates	--	--	--	--	--
Net P/L After M.I & Associates	143.08	118.83	84.63	109.68	84.48
Equity Share Capital	10.26	10.23	10.21	10.20	4.53
Reserves Excluding Revaluation Reserves	785.45	646.96	534.52	458.02	354.47
Equity Dividend Rate (%)	--	--	--	--	--
EPS Before Extra Ordinary	--	--	--	--	--
Basic EPS	13.95	11.62	8.29	10.76	8.28
Diluted EPS	13.92	11.59	8.26	10.69	8.28
EPS After Extra Ordinary	--	--	--	--	--
Basic EPS	13.95	11.62	8.29	10.76	18.78
Diluted EPS	13.92	11.59	8.26	10.69	8.28



KEY FINANCIAL RATIOS


AS OF MAR '25

Consolidated Key Financial Ratios	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
Investment Valuation Ratios	--	--	--	--	--
Face Value	1.00	1.00	1.00	1.00	1.00
Dividend Per Share	--	--	--	--	--
Operating Profit Per Share (Rs)	26.62	21.58	17.83	19.98	36.62
Net Operating Profit Per Share (Rs)	66.39	53.52	44.99	45.35	83.13
Free Reserves Per Share (Rs)	--	--	--	--	--
Bonus in Equity Capital	55.19	55.34	55.49	55.55	--
Profitability Ratios	--	--	--	--	--
Operating Profit Margin(%)	40.09	40.32	39.63	44.05	44.05
Profit Before Interest And Tax Margin(%)	28.95	28.82	25.41	31.77	29.72
Gross Profit Margin(%)	29.73	29.91	26.19	32.65	30.66
Cash Profit Margin(%)	30.78	31.42	31.03	34.37	34.88
Adjusted Cash Margin(%)	30.78	31.42	31.03	34.37	34.88
Net Profit Margin(%)	20.99	21.69	18.42	23.72	22.42
Adjusted Net Profit Margin(%)	20.44	20.89	17.87	23.08	21.73
Return On Capital Employed(%)	27.76	28.10	24.68	34.94	35.04
Return On Net Worth(%)	17.98	18.08	15.53	23.42	23.53
Adjusted Return on Net Worth(%)	18.20	18.51	15.64	23.63	23.71
Return on Assets Excl. Revaluations	77.86	64.48	53.55	46.05	79.27
Return on Assets Incl. Revaluations	77.86	64.48	53.55	46.05	79.27
Return on Long Term Funds(%)	27.76	28.10	24.68	34.99	35.15
Liquidity And Solvency Ratios	--	--	--	--	--
Current Ratio	0.32	0.38	0.53	1.04	1.31
Quick Ratio	0.31	0.36	0.50	0.99	1.28
Debt Equity Ratio	--	--	--	--	0.01
Long Term Debt Equity Ratio	--	--	--	--	0.01
Debt Coverage Ratios	--	--	--	--	--
Interest Cover	8.26	7.70	6.42	9.96	8.35
Total Debt to Owners Fund	--	--	--	0.00	0.01
Financial Charges Coverage Ratio	10.90	10.08	9.37	13.16	11.66
Financial Charges Coverage Ratio Post Tax	8.99	8.33	7.99	10.87	9.85
Management Efficiency Ratios	--	--	--	--	--
Inventory Turnover Ratio	138.14	105.70	224.16	108.11	142.47
Debtors Turnover Ratio	43.96	42.58	47.69	56.13	--
Investments Turnover Ratio	0.86	0.83	0.84	0.99	1.04
Fixed Assets Turnover Ratio	0.69	0.59	0.58	0.80	0.88
Total Assets Turnover Ratio	1.04	1.05	0.85	1.00	1.05
Asset Turnover Ratio	0.88	0.84	0.90	1.11	--
Average Raw Material Holding	--	--	--	--	--
Average Finished Goods Held	--	--	--	--	--
Number of Days In Working Capital	-214.58	-152.13	-142.09	-29.09	25.22
Profit & Loss Account Ratios	--	--	--	--	--
Material Cost Composition	--	--	--	--	--
Imported Composition of Raw Materials	--	--	--	--	--
Selling Distribution Cost Composition	1.14	0.75	0.73	0.36	0.36
Expenses as composition of Total Sales	--	--	--	--	--
Cash Flow Indicator Ratios	--	--	--	--	--
Dividend Payout Ratio Net Profit	7.17	8.60	12.05	--	--
Dividend Payout Ratio Cash Profit	4.80	5.81	6.97	--	--
Earning Retention Ratio	92.92	91.60	88.03	100.00	100.00
Cash Earning Retention Ratio	95.24	94.28	93.06	100.00	100.00
AdjustedCash Flow Times	--	--	--	0.00	0.03



SHAREHOLDING PATTERN

AS OF DEC '25



Promoter	52.60%
FII	15.10%
DII	28.59%
Public	3.14%
Others	0.57%



SUMMARY

- On quarterly basis, the Company delivered steady performance in Q3 of FY'26, with Net Sales up by 21.44% i.e. Rs. 205.21 crs in Dec '25 as compared to Rs. 168.98 crs in Dec '24. Moreover, the Net Profits too showed a rise of 22.81% i.e. Rs. 43.18 crs in Dec '25 as compared to Rs. 35.16 crs in Dec '24. In addition to this, the Statement of Changes in Equity witnessed an increase in the Equity Capital i.e. Rs. 10.27 crs in Dec '25 juxtapose to Rs. 10.26 crs in Dec '24.
- As per sound financials and healthy fundamentals, the Company is available at a good price of Rs. XXX with its 52 week low at Rs. 813.15 and its 52 week high at Rs. 1,180.00.
- Since the Promoters are holding a majority stake around 52.60%, it is fair to assume that the Management is committed to growth of the Company.
- The Shareholding Pattern shows that the FIIs and the Other DIIs collectively stood with 15.71% stake. Whilst, the Mutual Fund Houses own 27.98% holdings in the Company.
- It is reassuring to see that Vijaya Diagnostic Centre Limited is held by AXIS MF, BAJAJ FINSERV MF, EDELWEISS MF, HSBC MF, ICICI PRU MF, KOTAK MF, NIPPON MF, TATA MF, UNION MF, UTI MF & WHITEOAK MF.
- On consolidated basis, Vijaya Diagnostic Centre Limited registered Return on Equity (ROE) and Return on Capital Employed (ROCE) around 17.98% & 27.76% respectively as on Mar '25.
- For the year ending Mar '25, Vijaya Diagnostic Centre Limited has declared an equity dividend of 100.00% Rs. 1.00 per equity share.



DISCLOSURES

Copyright © Parveen Kumar Sharma, Proprietor of 10Paisa.com. Any act of copying or distributing this report in part or in full, for any purpose, without my permission, is strictly prohibited and would be a copyright infringement.

Disclosures as required under SEBI (Research Analyst) Regulations, 2014

Introduction:

I, Parveen Sharma, am the proprietor of 10Paisa.com and a SEBI-registered Research Analyst (Registration No.: INH100006427). I provide research and advisory services through my website, 10Paisa.com, which primarily focuses on the analysis of small-cap stocks in India. I have been offering stock recommendations through the platform since November 2004. Prior to obtaining SEBI registration, I developed extensive educational material comprising over 500 slides covering fundamental analysis, technical analysis, and value investing, which were used for investor education purposes.

Business Activity:

I provide research services on equity stocks listed on Indian stock exchanges. The research is based on fundamental analysis. I do thorough research and analysis on fundamentals of companies. As such, I undertake extensive scrutiny of major Company statistics like Balance Sheet, Profit & Loss Account, Key Financial Ratios (ROE, ROCE and Debt to Equity etc.), Quarterly, Half-yearly & Annual Results, Cash Flows, Annual Reports and Shareholding Pattern etc. Each Company's Business Model, Future Projections, Competitive Advantages & other Moats are thoroughly checked before recommending their Stock.

I offer services to the subscribers through the following:

1. 10Paisa.com
2. Midcaps.in
3. MidtoMega.com
4. SmallStocks.in
5. Largecaps.in

Disciplinary History

There is no disciplinary action which is / was running / initiated against me or my firm and there are no out-standing litigations against me.

General Terms and Conditions for 10Paisa.com:

1. Every week, 2 stock recommendations will be provided to the subscribers.
2. The subscribers have to login in their account through login credentials provided to them at the time of subscription.
3. The reports should not be considered as an investment advice or personal recommendation.
4. I and my team members will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided in the reports.
5. All of the views and opinions expressed in research reports, issued after due diligence and careful study, reflect my unbiased analysis of the Company or Companies as on the date of the report.
6. Still, it is advised that the users should rely on their own research and analysis as well as consult their own investment advisors to determine the suitability of recommendation.
7. Past performance of a Company is no guarantee for future performance or future results.
8. My service is not suitable to investors who are looking for intraday calls i.e. day trading or futures & options in stocks and indexes on basis of technical analysis.

[Click here](#) to view the terms and conditions of the website.



List of Associates / Relatives:

1. My spouse, Mrs. Priya Sharma
2. My daughter, Ms. Priyanka Sharma
3. My son, Master Priyanshu Sharma

Note: Subject Company is a company on which buy/sell recommendation or target price is given or changed in the research report.

Disclosure with regards to ownership and material conflicts of interest:

1. Neither I nor my associates / relatives have financial interest in the subject company.
2. Neither I nor my relatives / associates have actual/beneficial ownership of 1% or more in securities of the subject company, at the end of the month immediately preceding the date of publication of the document.
3. Neither I nor my relatives / associates have any other material conflict of interest at the time of publication of the document.

Disclosure with regards to receipt of compensation:

1. Neither I nor my associates / relatives have received any compensation from the subject company in the past 12 months.
2. Neither I nor my associates / relatives have managed or co-managed public offering of securities for the subject company in the past 12 months.
3. Neither I nor my associates / relatives have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
4. Neither I nor my associates / relatives have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
5. Neither I nor my associates / relatives have received any compensation or other benefits from the subject company or third party in connection with the document.

General Disclosures:

1. I have not served as an officer, director or employee of the subject company.
2. I am not engaged in market making activity for the subject company.

Definition of terms used:

1. Buy Recommendation: The subscribers can buy the shares of the subject company at the current market price.
2. Sell Recommendation: The subscribers can sell the shares of the subject company when the market price of the subject company hits the target price.

"Investments in Securities Market are subject to market risks. Read all the related documents carefully before investing".

"Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors".

Mr. Parveen Kumar Sharma, Proprietor of 10Paisa.com
SEBI Registered "Research Analyst" Reg. No. INH100006427
Contact: 7814321795
Email: tenpaisa@gmail.com
Address: #582, Phase 2, Mohali (Pb.)

OUR RESEARCH NETWORK

EXPLORE SPECIALISED RESEARCH PLATFORMS WITHIN OUR NETWORK



EMERGING SMALLCAP
STOCK RESEARCH

[VIEW WEBSITE](#)



DYNAMIC MIDCAP
STOCK RESEARCH

[VIEW WEBSITE](#)



CORE LARGE CAP
STOCK RESEARCH

[VIEW WEBSITE](#)



STOCKS BELOW
HUNDRED RUPEES

[VIEW WEBSITE](#)



LONG HORIZON
STOCK RESEARCH

[VIEW WEBSITE](#)

33+ YEARS OF EXPERIENCE

780+ REPORTS GENERATED

42+ SECTORS ANALYSED

18,000+ RESEARCH HOURS